Skip to main
BTSG

BTSG Stock Forecast & Price Target

BTSG Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrightSpring Health Services Inc. has demonstrated robust performance in its OP Rehab segment, which is growing at a strong rate while generating attractive profit margins. The company's management anticipates further margin improvement and increased EBITDA opportunities through selective mergers and acquisitions, positioning BrightSpring to capture a larger share of the generic drug market. Additionally, the expected uptick in EBITDA estimates for 2026-2027, driven by operational initiatives and continued growth from specialty pharmacy and generic conversions, underscores a positive financial outlook for the company.

Bears say

BrightSpring Health Services Inc. faces a challenging outlook due to potential vulnerabilities in client budget priorities, which could significantly impact the company’s revenue streams. The company's reliance on the Pharmacy Solutions segment for the majority of its revenue, combined with the risks associated with declining prescription rates and drug utilization, poses a threat to its operating results and cash flows. Additionally, the company's substantial debt load may hinder its ability to invest in growth, further complicating its market position and expansion prospects.

BTSG has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BrightSpring Health Services Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BrightSpring Health Services Inc (BTSG) Forecast

Analysts have given BTSG a Buy based on their latest research and market trends.

According to 9 analysts, BTSG has a Buy consensus rating as of Jan 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BrightSpring Health Services Inc (BTSG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.